

ABSTRACT

The invention relates to a novel antigen that is capable of stimulating the T-cell lymphocyte surface receptor CD40. The adjuvant is a ligand adapted for this purpose. The invention also relates to a novel vaccine incorporating the
5 aforementioned adjuvant and also ideally an antigen that is either a T-cell dependent antigen or a T-cell independent antigen.

09938477.082401